BCAB Live signaler | Maksimer profitt med Getagraph.com

SELG 137143 min ago

@ $2.35

Utstedt: 14 feb 2024 @ 15:33

Avkastning: 20.43%

Forrige signal: feb 12 - 16:14

Forrige signal: Kjøp

Avkastning: -12.31 %

Live Chart Being Loaded With Signals

Commentary (17 mai 2024 @ 22:00):

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer...

Stats
Dagens volum	570 285
Gjennomsnittsvolum	642 980
Markedsverdi	136.17M
EPS	$0 ( 2024-05-14 )
Neste inntjeningsdato	( $-0.490 ) 2024-08-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.140
ATR14	$0.00800 (0.28%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-30	Sievers Eric	Sell	572	Common Stock
2024-04-30	Smith Scott Andrew	Sell	2 181	Common Stock
2024-03-31	Smith Scott Andrew	Sell	2 181	Common Stock
2024-03-31	Sievers Eric	Sell	572	Common Stock
2024-02-29	Smith Scott Andrew	Sell	2 181	Common Stock

INSIDER POWER
93.68
Last 100 transactions
Buy: 3 003 180 \| Sell: 89 297

Volum Korrelasjon

Lang: -0.09 (neutral)

Kort: 0.81 (strong)

Signal:(37.396) Same movement expected

BioAtla, Inc. Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

BioAtla, Inc. Korrelasjon - Valuta/Råvare

-0.06
( neutral )

-0.11
( neutral )

0.00
( neutral )

0.24
( neutral )

0.00
( neutral )

0.38
( neutral )

BioAtla, Inc. Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-1.22M (0.00 %)
EPS:	$-2.58

FY	2023
Omsetning:	$0
Bruttogevinst:	$-1.22M (0.00 %)
EPS:	$-2.58

FY	2022
Omsetning:	$0
Bruttogevinst:	$-1.20M (0.00 %)
EPS:	$-2.70

FY	2021
Omsetning:	$250 000
Bruttogevinst:	$250 000 (100.00 %)
EPS:	$0

Financial Reports:

No articles found.

BioAtla, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

BioAtla, Inc.

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.